Navigation Links
Thoratec Schedules Fourth Quarter Conference Call, Webcast
Date:1/25/2012

PLEASANTON, Calif., Jan. 25, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for fiscal year 2011 on Wednesday, February 8.

The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Standard Time (4:30 p.m., Eastern Standard Time), Wednesday, February 8, hosted by Gary F. Burbach, President and Chief Executive Officer.

The teleconference can be accessed by calling (719) 325-2286, passcode 8725848. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available on the Internet at http://edge.media-server.com/m/p/qzi9ctde/lan/en, or http://www.thoratec.com.

A replay of the conference call will be available through Wednesday, February 15, via http://www.thoratec.com, or by telephone at (719) 457-0820, passcode 8725848.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate, HeartMate II and GoGear are registered trademarks of Thoratec Corporation. Cent
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Nile Therapeutics,Inc. (Nasdaq: NLTX ), today announced ... failure patient in its Phase IIa, multi-center, open-label,ascending ... candidate,CD-NP, a novel chimeric natriuretic peptide, in development ... The primary objective of the Phase IIa study ...
... 10 Medarex, Inc.,(Nasdaq: MEDX ) today ... in research discovery and antibody development, and the,multiple ... value.,In addition, comprehensive updates on current and future ... were presented by Medarex,s,President and CEO, Howard H. ...
Cached Medicine Technology:Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients 2Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients 3Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 2Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 3Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 4Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 5Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 6
(Date:7/11/2014)... Ohio (PRWEB) July 11, 2014 As ... 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number of ... blood sugar, abdominal issues and even death from the ... , According to the Times report , a ... in 2013 reported by patients was almost 14% of ...
(Date:7/11/2014)... Wash.The largest study of its kind has found ... of advantages over their conventional counterparts, including more ... The study looked at an unprecedented 343 peer-reviewed ... organic and conventional plant-based foods, including fruits, vegetables, ... techniques to quantify differences between organic and non-organic ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... from the worldwide scourge of dengue fever was somewhat successful ... only prevented dengue fever in 56 percent of the 10,000 ... protected more than 88 percent of them from severe disease. ... and sometimes death. "This vaccine has already proven to ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
(Date:7/11/2014)... Europe is one of the largest consumers of ... land area. The agricultural sector is a significant user ... of the total water use. The scale and importance ... but far from negligible in most northern ones. , ... of the water use in most countries, while in ...
Breaking Medicine News(10 mins):Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3
... the surgical treatment of retinal hemorrhages or injuries. The purpose ... to the wall of the eye. There is a risk ... at high altitudes, or under nitrous oxide anesthesia. This expansion ... for weeks after the surgical procedure. , In order to ...
... with a FREE Box of Healthy ... Feb. 25 Every four years, Leap Day,gives us an extra ... you to use that extra day -- which is also the ... help people take,a small leap to healthier eating, the makers of ...
... University of Maryland at College Park have discovered that ... with elevated zinc level, at the high end of ... cell growth, up-regulation of growth arrest and DNA damage-induced ... G2/M cell cycle progression. The research, published in the ...
... who are highly anxious about their skin condition say they ... to new research at the University of Bath (UK). , ... 50 young to middle-aged adults recruited from a national acne ... less likely to participate in sport or exercise, acne sufferers ...
... with Accumulator(R) Variable ... Annuity, ... in retirement, AXA Equitable Life,Insurance Company is offering a new way to ... company,s top-selling,Accumulator(R) variable annuity provides for a minimum 200% benefit base,guarantee if ...
... continues to add,new companies to their customer ... licenses. In the last year, Billian,s HealthDATA ... to provide their,customers, with meticulously researched, cutting-edge ... current information to guide informed,decisions about the ...
Cached Medicine News:Health News:'Free For All' on Leap Day to Get Hearts Pumping! 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 3Health News:Acne may prevent people from participating in sport and exercise, says research 2Health News:AXA Equitable Helps Americans Prepare for a Long Retirement 2Health News:AXA Equitable Helps Americans Prepare for a Long Retirement 3Health News:AXA Equitable Helps Americans Prepare for a Long Retirement 4Health News:Billian's HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence 2Health News:Billian's HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence 3
... Access ...unlike any trocar system you've ever ... actually four systems in one designed ... adaptive to all of your needs., ... or dilating tip styles, OnePort™ can effectively ...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
... FPK01 Thoracic Trocar Pak contains: ... flexible sleeves and (1) 12mm ... ,FPK02 Thoracic Trocar Pak contains: ... flexible sleeves., ,FPK03 Thoracic ...
... The FLEXIPATH Flexible Surgical ... solid or mechanical obturator and ... designed to prevent puncture or ... flexible sleeve has securing holes ...
Medicine Products: